Saturday - September 13, 2025
NIH Eyes Exclusive Patent License for Immunotoxin Technology
September 10, 2025
WASHINGTON, Sept. 10 (TNSFR) -- The U.S. Department of Health and Human Services National Institutes of Health is evaluating a possible exclusive patent license to Lysin Therapeutics Inc., Silver Spring, Maryland. The proposed agreement would grant the company the rights to several patents related to the development of immunotoxins for treating cancer.

The patents encompass multiple inventions, including improved Pseudomonas Exotoxin A with reduced immunogenicity, Pseudomonas Exotox . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products